Yamada rejoins Frazier Healthcare

Frazier Healthcare said Monday that Tadataka Yamada, Ph.D., has rejoined the firm as a Venture Partner on the Life Sciences team. He will also serve as a Senior Advisor to the Growth Buyout team. Before rejoining Frazier, Dr. Yamada was Chief Medical and Scientific Officer at Takeda Pharmaceuticals in Tokyo, as well as a member of the Board of Directors.

VC-backed Cidara Therapeutics rolls out IPO

San Diego-based biotech company Cidara Therapeutics has raised $76.8 million for its IPO after pricing its 4.8 million shares at $16 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “CDTX.” Jefferies LLC and Leerink Partners are the lead underwriters. Cidara’s backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.


Collegium Pharmaceutical grabs $50 mln

Canton, Massachusetts-based Collegium Pharmaceutical Inc, a specialty pharmaceutical company focused on treating chronic pain, has secured $50 million in funding. TPG Biotech led the round with participation from RA Capital Management, Adage Capital Management, Rock Springs Capital, EcoR1 Capital, Eventide Asset Management, Aperture Venture Partners, Longitude Capital, Skyline Ventures, Frazier Healthcare and Boston Millennia Partners. In conjunction with this financing, Dr. Eran Nadav, a partner and managing director at TPG Biotech, has been added to Collegium’s board of directors.


Durand joins Frazier Healthcare

Remy Durand has joined Frazier Healthcare as a senior associated. He will focus on investment identification, due diligence and deal closing. Most recently, Durand was a member of the investment team at GE Ventures and a management consultant in L.E.K. Consulting’s life science practice.

Merganser Biotech snags $28 mln Series A

Merganser Biotech Inc, which focuses on treating rare blood and iron-related diseases, has secured $28 million in Series A financing. Novartis Venture Fund led the round with participation from Frazier Healthcare, Sutter Hill Ventures, Osage University Partners, BioAdvance and Stateside Developments. In addition to the funding, Markus Goebel of Novartis Venture Fund, James Topper of Frazier Healthcare and Jeffrey Bird of Sutter Hill Ventures have been added to Merganser’s board of directors. Also, Bill Harrington of Osage University Partners has been named as a board observer.

Laguna Pharmaceuticals grabs $30 mln Series B, also appoints CEO

Laguna Pharmaceuticals, formerly known as ChanRx, has closed $30 million in Series B financing. Versant Ventures and Frazier Healthcare led the round with participation from BioMed Ventures and previous backer Sante Ventures. In addition to the financing, Dr. Jerel Davis of Versant Ventures and Dr. Jamie Topper of Frazier Healthcare have been added to Laguna’s board of directors. Also, Laguna Pharmaceuticals has hired Bob Baltera as CEO. Previously, Baltera was CEO of Amira Pharmaceuticals. Laguna Pharmaceuticals is a biopharmaceutical company focused on treating atrial fibrillation and atrial flutter.

Moraski named Frazier Healthcare operating partner

Frazier Healthcare said that Brett Moraski has joined the growth buyout team as an Operating Partner. Previously, Moraski was a Senior Operating Advisor at LLR Partners and Corporate VP of Transformation at WellPoint. With offices in Seattle and Menlo Park, California, Frazier provides venture and growth capital to healthcare companies.


Frazier Healthcare expands team with two hires

Frazier Healthcare, which provides growth financing to healthcare firms, has added Bob Lefton and Bob Zollars to its growth buyout team. Zollars will serve as an operating partner while Mr. Lefton becomes a senior advisor. Lefton is co-founder. executive chairman and a director of DSI Renal. And, Zollars is the chairman of the board of Vocera.

Allena Pharma raises $25 mln

Allena Pharmaceuticals has completed a $25 million Series B financing led by HBM Partners. Existing investors Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners and new investor Pharmstandard International also participated. Newton, Mass.-based Allena is specialty biopharmaceutical company that develops non-systemic protein therapeutics to treat metabolic and orphan diseases.

Imago BioSciences fetches $26.5 mln Series A

San Francisco-based biotech firm Imago BioSciences has closed $26.5 million in Series A funding. Clarus Ventures led the round with participation from other investors that included Frazier Healthcare, Amgen Ventures and Merck Research Labs Venture Fund. In conjunction with the funding, representatives from Clarus Ventures and Frazier Healthcare have been added to the the company’s board of directors.


NEA adds new partner to team

New Enterprise Associates has hired Dr. Carol Gallagher as a partner at its Menlo Park office. Previously, she was the chairman of eFFECTOR Therapeutics, a director at Aragon Pharmaceuticals (which was bought by Johnson & Johnson in 2013) and a venture partner with Frazier Healthcare.


Frazier Healthcare’s PCI buys Biotec

PCI, a portfolio company of Frazier Healthcare, said Friday that it has acquired Biotec. No financial terms were disclosed. Teneo Capital provided financial advice to PCI and Frazier Healthcare for this transaction. Based in the UK, Biotec is a provider of clinical trial services and temperature controlled pharmaceutical solutions.


Frazier Healthcare expands team with new hire

Frazier Healthcare said Friday that it has hired David Socks as a venture partner in its Boston office. Previously, Socks worked at Incline Therapeutics where he served as its president and COO until the company was sold to The Medicines Company.


Frazier Healthcare’s PCI agrees to acquire Penn Pharma

Packaging Coordinators, a portfolio company of Frazier Healthcare, has agreed to buy Penn Pharma. No financial terms were disclosed. Headquartered in Tradegar, Wales with offices in New Hope, Penn. and Tokyo, Penn Pharma is a provider of drug development and manufacturing services.


Cidara Therapeutics snags $32 mln Series A

Biopharmaceutical firm Cidara Therapeutics said Monday that it has secured $32 million in Series A funding. 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners were the lead investors. In addition to the financing, the firm has hired Dr. Jeffrey Stein as president and CEO. It has also named Dr. Kevin Judice and Dr. H. Shaw Warren as chief operating officer and chief scientific officer respectively. Warren will also join Cidara’s scientific advisory board.  And, Dr. Ken Bartizal has been added as chief development officer while Dr. Dirk Thye has joined Cidara as chief medical officer.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget